📊 JBIO Key Takeaways
Is Jade Biosciences, Inc. (JBIO) a Good Investment?
Pre-revenue biotech company facing critical cash runway crisis with less than 12 months of operations funded at current burn rate. Accelerating net losses (-27.2% YoY) and $94.7M annual operating cash burn against only $88.4M cash position create severe financial distress requiring immediate capital infusion or revenue generation to avoid potential restructuring.
Jade Biosciences appears to be a pre-revenue biotech with strong liquidity and no debt, but fundamentals show deep operating and net losses with worsening YoY profitability. With ~$88M in cash against roughly ~$95M annual operating cash outflow, runway is limited and external financing is likely. Until cash burn moderates and there is tangible progress toward revenue or non-dilutive funding, the risk profile remains unfavorable.
Why Buy Jade Biosciences, Inc. Stock? JBIO Key Strengths
- Zero debt capital structure eliminates refinancing risk and limits downside
- Excellent liquidity position (21.09x current ratio) enables continued near-term operations
- Substantial stockholders' equity base ($332.5M) provides bankruptcy cushion and dilution capacity
- Exceptional liquidity (21.09x current/quick ratio)
- Debt-free balance sheet with minimal interest burden
- Large equity base relative to modest liabilities
JBIO Stock Risks: Jade Biosciences, Inc. Investment Risks
- Critical cash runway of approximately 11 months at current burn rate with no path to profitability visible
- Accelerating net losses ($127.4M) with 27.2% year-over-year deterioration indicates worsening financial condition
- Massive operating cash burn ($94.7M annually) against zero revenue indicates pre-commercialization biotech with execution risk
- Severe shareholder dilution inevitable as company will require emergency capital raise to survive
- Negative ROE (-38.3%) and ROA (-36.4%) indicate value destruction at current burn trajectory
- Pre-revenue status with substantial operating losses
- Limited cash runway given current burn rate
- High dilution/financing risk to sustain operations
Key Metrics to Watch
- Quarterly operating cash flow trend and remaining months of runway
- Revenue generation or commercialization milestone announcements
- Capital raise announcements and dilution impact to existing shareholders
- Quarterly operating cash burn (OCF)
- Cash & equivalents (runway months)
Jade Biosciences, Inc. (JBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 21.09x current ratio provides a solid financial cushion.
JBIO Profit Margin, ROE & Profitability Analysis
JBIO vs Healthcare Sector: How Jade Biosciences, Inc. Compares
How Jade Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Jade Biosciences, Inc. Stock Overvalued? JBIO Valuation Analysis 2026
Based on fundamental analysis, Jade Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Jade Biosciences, Inc. Balance Sheet: JBIO Debt, Cash & Liquidity
JBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Jade Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.89 indicates the company is currently unprofitable.
JBIO Revenue Growth, EPS Growth & YoY Performance
Jade Biosciences, Inc. Dividends, Buybacks & Capital Allocation
JBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Jade Biosciences, Inc. (CIK: 0001798749)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JBIO
What is the AI rating for JBIO?
Jade Biosciences, Inc. (JBIO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JBIO's key strengths?
Claude: Zero debt capital structure eliminates refinancing risk and limits downside. Excellent liquidity position (21.09x current ratio) enables continued near-term operations. ChatGPT: Exceptional liquidity (21.09x current/quick ratio). Debt-free balance sheet with minimal interest burden.
What are the risks of investing in JBIO?
Claude: Critical cash runway of approximately 11 months at current burn rate with no path to profitability visible. Accelerating net losses ($127.4M) with 27.2% year-over-year deterioration indicates worsening financial condition. ChatGPT: Pre-revenue status with substantial operating losses. Limited cash runway given current burn rate.
What is JBIO's revenue and growth?
Jade Biosciences, Inc. reported revenue of N/A.
Does JBIO pay dividends?
Jade Biosciences, Inc. does not currently pay dividends.
Where can I find JBIO SEC filings?
Official SEC filings for Jade Biosciences, Inc. (CIK: 0001798749) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JBIO's EPS?
Jade Biosciences, Inc. has a diluted EPS of $-3.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Jade Biosciences, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JBIO stock overvalued or undervalued?
Valuation metrics for JBIO: ROE of -38.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JBIO stock in 2026?
Our dual AI analysis gives Jade Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JBIO's free cash flow?
Jade Biosciences, Inc.'s operating cash flow is $-94.7M, with capital expenditures of $196.0K.
How does JBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -38.3% (avg: 15%), current ratio 21.09 (avg: 2).